SEC Form 4 · accession 0001209191-16-125663
Pediatrix Medical Group, Inc. · MD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D Stanley
Officer — President, Clinical Services
Period of report
Jun 1, 2016
Accepted (ET)
Jun 3, 2016 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000893949
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2016 | A | 12,135 | $0.00 | A | 49,266 | D | |
| Common StockF3,F4 | Jun 1, 2016 | S | 14,778 | $67.7838 | D | 35,247 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 3,034 additional shares based on the achievement of certain performance-based criteria for the period from April 1, 2016 through March 31, 2017. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three equal installments on June 1, 2017, June 1, 2018 and June 1, 2019.
- F2Sales made pursuant to Reporting Person's 105b-1 trading plan.
- F3Sales of shares were made in thirty-seven separate transactions with prices ranging from $67.56 to $67.95 for a weighted average sales price of $67.7838.
- F4Includes 759 restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, as amended, in connection with achievement in excess of target of specified performance-based criteria for the performance period from April 1, 2015 through March 31, 2016, which restricted shares were not previously reported. The additional restricted shares vest in three equal installments on June 1, 2016, June 1, 2017 and June 1, 2018, subject to continued employment.